Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Rigel Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was €337.8 Mil.
Rigel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €110.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rigel Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's EV-to-EBIT falls into.
Rigel Pharmaceuticals's current Enterprise Value is €520.6 Mil.
Rigel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €110.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a EV-to-EBIT of 4.69 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #135 out of 378 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Rigel Pharmaceuticals' EV-to-EBIT too high?
Rigel Pharmaceuticals' current EV-to-EBIT is 4.69. The Biotechnology industry median EV-to-EBIT is 12.77. Rigel Pharmaceuticals' value of 4.69 is 63.3% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #135 out of 378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' EV-to-EBIT compare to SGP and OCS?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #135 out of 378 companies for EV-to-EBIT. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 12.77. Rigel Pharmaceuticals' value of 4.69 is 63.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.77, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current EV-to-EBIT of 4.69 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current EV-to-EBIT is 4.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €24.56, compared to a current price of €33.10 — trading 34.8% above its estimated fair value. The current EV-to-EBIT is 4.69 and 63.3% below the Biotechnology industry median of 12.77. Rigel Pharmaceuticals' overall GF Score™ is 24/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current EV-to-EBIT is 4.69 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €33.10 is trading 34.8% above its estimated GF Value™ of €24.56.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:RI2:
EV-to-EBIT: 4.69
GF Value™: €24.56 vs. price of €33.10 (34.8% above fair value)
Industry Position: 63.3% below the Biotechnology median (#135 of 378)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
24GF Score
Get the complete analysis for FRA:RI2
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
